Ivantis, a US-based healthcare company dedicated to developing treatments for glaucoma eye disease, has secured an additional $5m in the second close of its series B financing, led by EDBI, the corporate investment arm of Singapore’s Economic Development Board.
In January, Ivantus raised $27m in its series B round from a consortium led by faith-based healthcare corporate venture fund Ascension Health Ventures as a new investor. Venture capital firms New Enterprise Associates (NEA) and Delphi Ventures, and MemorialCare Innovation Fund…
